Tricuspid valve replacement outcomes by baseline tricuspid regurgitation severity: the TRISCEND II trial.
Lurz P, Hahn RT, Kodali S, Makkar R, Sharma RP, Davidson CJ, O'Neill BP, Yadav P, Zahr F, Chadderdon S, Eleid MF, Szerlip M, Smith R, Whisenant B, Garcia S, Kister T, Kipperman RM, Lim S, Saxon J, Kapadia S, Hermiller J, Mishell JM, Rassi A, Herrmann HC, Szeto W, Hausleiter J, Babaliaros V, Barker CM, Lindman BR, Latib A, Muhammad K, von Bardeleben RS, Summers M, Chetcuti S, Ailawadi G, Russo M, Rinaldi M, Chehab BM, Nickenig G, Stinis C, Inglessis-Azuaje I, Dhoble A, Chhatriwalla AK, Petrossian G, Shah P, Staniloae C, Williams M, Nores M, McCabe JM, Singh G, Baldus S, Rudolph V, Barb I, Klodell C, Gray W, Strote J, Sannino A, Grayburn P, Mack MJ, Leon MB, Thourani VH.
Lurz P, et al. Among authors: stinis c.
Eur Heart J. 2025 Aug 29:ehaf676. doi: 10.1093/eurheartj/ehaf676. Online ahead of print.
Eur Heart J. 2025.
PMID: 40878717